Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | President and COO | November 15, 2024 | November 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date November 15, 2024 · Filed November 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 506,852 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Tax withholding · Disposed 14,286 · Balance 506,852 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2028-07-22 | Direct | 452,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 452,000 F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 434,122 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 434,122 F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 159,226 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 159,226 F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 4,784 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4,784 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 150,000 F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 447,917 |
Reported balance
Holding disclosure · report date 2024-11-15 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 447,917 F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F3: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F4: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
F6: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2023 Filed Oct 2, 2023 22:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $7.72 | $23,159.40 |
DisclosureSEC source: 0001209191-23-051191 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,782 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.56 to $7.83 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 22:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-051191 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 22:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-047538 · doc4.xml · derivative · entry 5 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 22:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 63 | $9.45 | $595.55 |
DisclosureSEC source: 0001209191-23-047538 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,782 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $9.45 to $9.46 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 22:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 2,937 | $8.64 | $25,372.74 |
DisclosureSEC source: 0001209191-23-047538 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,845 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.42 to $9.36 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 24, 2023 Filed Aug 28, 2023 22:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-047538 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 22:41 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,378 | $9.18 | $49,370.04 |
DisclosureSEC source: 0001209191-23-046426 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,782 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| July 29, 2023 Filed Jul 28, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-043713 · doc4.xml · derivative · entry 5 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 532,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F5 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 4,373 | $14.05 | $61,423.60 |
DisclosureSEC source: 0001209191-23-043713 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 424,160 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.77 to $14.30 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,627 | $13.12 | $47,569.92 |
DisclosureSEC source: 0001209191-23-043713 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 428,533 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.77 to $13.74 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:50 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-23-043713 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 432,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 19:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-040504 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 540,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 19:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $7.49 | $22,470.00 |
DisclosureSEC source: 0001209191-23-040504 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 424,160 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.38 to $7.74 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 19:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-040504 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-033974 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,000 Underlying: Class A Common Stock · 3,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,000 | $8.63 | $25,888.20 |
DisclosureSEC source: 0001209191-23-033974 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,160 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.47 to $9.02 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 22:05 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 3,000 | $1.06 | $3,180.00 |
DisclosureSEC source: 0001209191-23-033974 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 427,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023. F2 · balance_after: Includes 1,731 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 22:19 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 5,415 | $5.60 | $30,324.00 |
DisclosureSEC source: 0001209191-23-030375 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,429 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-013329 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $7.82 | $62,540.00 |
DisclosureSEC source: 0001209191-23-013329 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,844 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.74 to $8.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-23-013329 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:16 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,603 | $8.44 | $13,529.32 |
DisclosureSEC source: 0001209191-23-010781 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,844 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 434,122 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001209191-23-007048 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,122 Underlying: Class A Common Stock · 434,122 shares Expires 2033-02-01 F5 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 3,093 | $8.55 | $26,445.15 |
DisclosureSEC source: 0001209191-23-007048 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,447 F4 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 9,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007048 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,540 F3 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:13 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 217,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007048 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,808 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter. F2 · balance_after: Includes 2093 shares acquired under the Recursion stock purchase plan on May 20, 2022. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-005316 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $8.07 | $64,547.20 |
DisclosureSEC source: 0001209191-23-005316 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,654 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.95 to $8.31 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| January 26, 2023 Filed Jan 27, 2023 22:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-23-005316 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-063013 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,000 Underlying: Class A Common Stock · 8,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,000 | $7.70 | $61,566.40 |
DisclosureSEC source: 0001209191-22-063013 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,654 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.28 to $7.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 29, 2022 Filed Dec 30, 2022 22:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 8,000 | $1.06 | $8,480.00 |
DisclosureSEC source: 0001209191-22-063013 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 23:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-057706 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,000 Underlying: Class A Common Stock · 16,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 23:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 16,000 | $10.96 | $175,401.60 |
DisclosureSEC source: 0001209191-22-057706 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,654 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.78 to $11.32 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 23:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 16,000 | $1.06 | $16,960.00 |
DisclosureSEC source: 0001209191-22-057706 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 23:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,453 | $11.86 | $17,232.58 |
DisclosureSEC source: 0001209191-22-057706 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,654 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 22:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-054855 · doc4.xml · derivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 586,000 Underlying: Class A Common Stock · 16,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 22:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 16,000 | $10.72 | $171,449.60 |
DisclosureSEC source: 0001209191-22-054855 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,107 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.35 to $11.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 22:07 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 16,000 | $1.06 | $16,960.00 |
DisclosureSEC source: 0001209191-22-054855 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 23:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-051979 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602,000 Underlying: Class A Common Stock · 16,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 23:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 64 | $11.53 | $737.92 |
DisclosureSEC source: 0001209191-22-051979 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,107 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 23:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 15,936 | $10.86 | $173,010.78 |
DisclosureSEC source: 0001209191-22-051979 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,171 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.52 to $11.47 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 23:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 16,000 | $1.06 | $16,960.00 |
DisclosureSEC source: 0001209191-22-051979 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-046463 · doc4.xml · derivative · entry 4 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,000 Underlying: Class A Common Stock · 16,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 16,000 | $12.60 | $201,636.80 |
DisclosureSEC source: 0001209191-22-046463 · doc4.xml · nonDerivative · entry 3 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,107 F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.06 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 22:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 16,000 | $1.06 | $16,960.00 |
DisclosureSEC source: 0001209191-22-046463 · doc4.xml · nonDerivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:34 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,453 | $12.96 | $18,830.88 |
DisclosureSEC source: 0001209191-22-046463 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,107 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 16, 2022 Filed May 18, 2022 23:15 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 1,458 | $5.67 | $8,266.86 |
DisclosureSEC source: 0001209191-22-030247 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,560 F1 · kind: Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:55 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 58,500 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-22-017387 · doc4.xml · derivative · entry 2 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634,000 Underlying: Class A Common Stock · 634,000 shares Expires 2028-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:55 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 58,500 | $1.06 | $62,010.00 |
DisclosureSEC source: 0001209191-22-017387 · doc4.xml · nonDerivative · entry 1 Larson Tina Marriott · CIK 0001856414 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.